![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression
Allogeneic mesenchymal stromal cells (MSCs) are a safe treatment option for many disorders of the immune system. However, clinical trials using MSCs have shown inconsistent therapeutic efficacy, mostly owing t...
-
Article
Who wins the combat, CAR or TCR?
Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell hematological malignancies. Eve...
-
Article
CAR-T Cell Therapy: the Efficacy and Toxicity Balance
Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy that has resulted in tremendous progress in the treatment of patients with B cell malignancies. However, the remarkable efficacy of therapy is...
-
Article
Open AccessClinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stop** ibrutinib due to toxicity. A better understanding of expected outcomes i...
-
Article
Open AccessTherapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
-
Article
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity
Inhibitory myeloid cells and their cytokines play critical roles in limiting chimeric antigen receptor T (CART) cell therapy by contributing to the development of toxicities and resistance following infusion. ...
-
Article
Open AccessChronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
The distinction between chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with isolated Hodgkin/Reed–Sternberg cells (CLL-HRS; background milieu with a paucity of inflammatory cells) and overt ...
-
Chapter
Combination Therapeutics with CAR-T Cell Therapy
Adoptive cellular immunotherapy, specifically chimeric antigen receptor T-cell (CAR-T) therapy, has recently emerged as a breakthrough treatment for multiple hematological malignancies with potential for long ...
-
Article
Open AccessCause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
-
Article
Open AccessDistinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
Richter syndrome (RS) refers to transformation of chronic lymphocytic leukemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma. RS is known to be associated with a number of geneti...
-
Article
Open AccessVenetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
-
Article
CRISPR Takes the Front Seat in CART-Cell Development
Chimeric antigen receptor T (CART)-cell immunotherapies have opened a door in the development of specialized gene therapies for hematological and solid cancers. Impressive response rates in pivotal trials led ...
-
Article
Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
Ibrutinib therapy is associated with an increased risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL). Risk assessment tools and outcomes of AF in these patients are not well described.
-
Article
Open AccessCART Cell Toxicities: New Insight into Mechanisms and Management
T cells genetically engineered with chimeric antigen receptors (CART) have become a potent class of cancer immunotherapeutics. Numerous clinical trials of CART cells have revealed remarkable remission rates in...
-
Article
Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes
-
Article
CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview
The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell (CAR T-cell) therapy and where it fits in the evolving landscape of the management of patients with refractory/rela...
-
Article
Human chimeric antigen receptor macrophages for cancer immunotherapy
Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging1–4. Given the unique effector functions of macrophages and th...
-
Article
CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
The advent of the genome editing era brings forth the promise of adoptive cell transfer using engineered chimeric antigen receptor (CAR) T cells for targeted cancer therapy. CAR T cell immunotherapy is probabl...
-
Article
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
Autologous, patient-specific chimeric antigen receptor T-cell (CART) therapy has emerged as a powerful and potentially curative therapy for cancer, especially for CD19-positive hematological malignancies. Inde...
-
Article
Open AccessTreatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells